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Summary.-The response of drug-resistant patients with acute leukaemia and
Burkitt's lymphoma to treatment with a 24 h infusion of methotrexate (MTX)
followed, in some cases, by cytosine arabinoside wascorrelated with in vitro measure-
ments of total intracellular MTX, exchangeable intracellular MTX, and suppres-
sibility of deoxyuridine (UdR) incorporation in isolated marrow blast cells at extra-
cellular MTX concentrations of 10-8M, 10-7M, 10-6M and 10-5M. Total intracellular
MTX levels and exchangeable intracellular MTX levels were not significantly dif-
ferent in responding or non-responding patients at any MTX concentration, but
increased four-fold for every ten-fold concentration increment studied. Extra-
cellular MTX levels in excess of 10-7M appeared necessary to allow accumulation of
exchangeable intracellular MTX. UdR incorporation at 10-6M and 10-5M differed
significantly between responding and non-responding patients, with responders
having < 20% of control values and non-responders having > 400/ of control values.
Further, increasing the extracellular MTX concentration from 10-6M to 10-5M
produced no significant decrease in UdR incorporation in either group. The thera-
peutic implications of this apparent threshold are discussed.
THE SENSITIVITY of certain human
neoplasms to MTX has been appreciated
for some time. Attempts to characterize
those pharmacological or biochemical
determinants which predict sensitivity
have been disappointing. Scrutiny of
drug uptake and its role in resistance has
produced conflicting data (Hall, Roberts
and Kessel, 1966; Hoffbrand et al., 1973;
Kessel, Hall and Roberts, 1968). Quanti-
tation and characterization of cellular
dihvdrofolate reductase (DHFR) have
shown no consistent differences between
sensitive and resistant cell populations
(Roberts and Hall, 1973). However, in-
hibition of leukaemic cell DHFR activity
was greatest in blast cells ofpatients whose
disease subsequently remitted on MTX
therapy (Hryniuk and Bertino, 1969).
Attempts to correlate this observation
with the in vitro incorporation ofUdR into
blast cell DNA, however, failed to be
predictive ofresponse to subsequent MTX
therapy. A similar study by Necheles,
Maniatis and Allen (1 968) suggests that
UdR incorporation was inhibited by 65%
or more in cells of responsive patients,
compared to 45% or less in those of
resistant patients, when exposed to extra-
cellular MTX concentrations of 2-2plM.
Recent work by Hyrniuk, Bishop and
Foerster (1974), which examines the
incorporation of [3H]thymidine into leu-
kaemic blasts in patients treated with
MTX, also suggests a predictive value for
an in vitro test.
Available techniques now permit iso-
lation of human marrow blast cells for
laboratory study (Evans, Wolf and
Chabner, 1974). This capability allows
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study ofMTX transport and UdR incorpo-
ration in previously treated patients with
low or absent peripheral blasts and with
marrow-dominant disease. The relation-
ship between their clinical response to
MTX therapy and these in vitro correlates
is the subject of this paper.
MATERIALS AND METHOI)S
Chemicals. [3', 5'-3H] MTXwas obtained
from Amersham/Searle Corp., Arlington
Heights, Ill. Unlabelled MTX was obtained
in powdered form from American Cyanamide
Co. (Lederle), Pearl River, N.Y. Purification
was carried out as previously described
(Goldman, Lichtenstein and Oliverio, 1968)
on a DEAE-cellulose column, using linear
gradient elution with ammonium bicaronate
buffer. [3H]UdR (sp. act., 15 Ci/mmol) was
also obtained from Amersham/Searle Corp.,
Arlington Heights, Ill.
Cells and media.-On the day prior to
treatment, leukaemic or lymphomatous cells
were obtained from the bone marrow
aspirates of 10 patients with marrow-domi-
nant disease resistant to drug combinations
containing MTX. Their diagnosis and pre-
vious therapies are summarized in Table I.
No patient received any chemotherapy
w%Nithin 2 weeks of study, nor had any patient
received MTX within 2 months of study.
Ten ml of bone marrow was aspirated into
plastic syringes containing no anticoagulant
and immediately expelled into 10 volumes of
4°C bicarbonate-buffered 0850° NaClsolution
(BBS) adjusted to pH 7-4. The subsequent
isolation of the immature marrow elements
was carried out according to the method of
Evans et al. (1974), substituting BBS for a
phosphate buffer (NaKP). Following a final
wash with 4°C BBS, the supernatant fraction
containingtheimmaturecells wasresuspended
in a suitable volume of 4°C Eagles minimal
essential medium without serum or folates,
and cell viability assessed by trypan blue
exclusion. All preparations had greater than
90%o viability by this technique. Smears of
the cell suspensions were also prepared at this
time using a Cyto-Centrifuge (8handon
Southern Instruments, Inc., Sewickley, Pa.)
from which differential cell counts were made.
All suspensions contained more than 80%
leukaemic or lymphomatous blast cells, the
remaining cells consisting of promyelocytes,
myelocytes, mature granulocytes, and occa-
sional lymphocytes. Less than 7,/% of the
cells in any suspension Mwere mature granulo-
TABLE I. Previous Treatment ofPatient Population
Duration of disease Previous
Patieilt Age (yr) Diagnosis (months) therapy
K.R. 31 AML 76 POMP, COAP,
Ara-C/6-TG,
Dnr, Aza-C
J.F. 21 ALL 21 POMP, VDP,
Asp
P.M. 11 ALL 75 POAMP, VDP,
Asp,
Ara-C/6-TG
C.F. 9 ALL 44 POMP, VDP,
Asp, COAP
D.B. 5 ALL 15 POMP, VDP,
Asp
P.J. 21 ALL 120 POMP, VDP,
Asp
K.T. 18 ALL 37 POMP, VDP,
Asp
S.Ly 7 BL 4 COM
S.Li 16 BL 7 Bleo, Vlb,
COM, Ara-C
P.R. 5 BL 3 COM, Adr
The abbreviations ise(d are: AML, acuite myelogenous leukaemia; ALL, acute
lymphocytic lettkaemia; BL, Burkitt's lymphoma; POMP, prednisone, oncovin,
m'zthotrexatc and 6-mer3aptopurine: COAP, cytoxan, oncovin, cytosine arabinoside
an(I predInisonie; Ara-C, cytosine arabinoside; 6-TG, 6-thioguaniine; Dnr, daunomycin;
Aza-C, 5-azacytidine; VDP, vincristine, daunomycin and prednisone; Asp, L-aspa-
ragiriase; COM, cytoxan. oncovin, methotrexate; Bleo, bleomycin; Vlb, velbaii; and
Adr, adiriamycin.
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cytes. Erythroid precursors, lymphoid pre-
cursors and mature lymphocytes were absent
from the final cell suspension.
Incubationtechniques.-Thecellsuspension
was adjusted to a cell count of5-10 X 105/ml,
and 2 ml of the suspension was added to an
equal volume of Eagle's medium containing
unlabelled MTX at twice the desired concen-
tration, or Eagle's medium containing no
drug, in control studies. The concentrations
of MTX chosen were 10-5M, 10-6M, 10-7M
and 10-8M, as this range encompassed both
the commonly used clinical range and the
95% inhibitory level (10-6M) reported
previously (Hryniuk and Bertino, 1969).
The cell suspensions were incubated in a
humidified atmosphere of95% 02-5% CO2 in
13-ml conical centrifuge tubes suspended in
an Eberbach shaker bath (Eberbach Corp.,
Ann Arbor, Mich.) at 37°C. Cells were
incubated for 120 min, an interval sufficient
to saturate all high-affinity intracellular
binding sites, and allow accumulation of
exchangeable intracellular MTX as well,
although cells from only acute
myelogenous leukaemia (AML) reached a
" steady-state " during this incubation period
(Bender, 1975). Following 120 minofuptake,
cell suspensions were pulsed with 10 pul of
[3H]UdR for an additional 40 min of
incubation. A total incubation time of 160
min was chosen, as cell viability began to
decline with further in vitro exposure.
Further, the work of Myers, Young and
Chabner (1975) suggests that alteration ofthe
deoxyuridylate pool in antimetabolite-
poisoned cells is negligible over this interval.
To terminate an incubation, 100 p-l of 5%
bovine albumin (Armour Pharmaceutical Co.,
Chicago, Ill.) in BBS was added to each tube,
followed by 4 ml of 20% ice-cold trichloro-
acetic acid (TCA). The tubes were then
capped, centrifuged at 4°C at 700 g for 10 min,
and the supernatant decanted. The pellet
was resuspended in 4 ml ofice-cold 5% TCA,
centrifuged at 700 g for 10 min, and the
supernatant discarded. This procedure was
repeated 4 more times, until the radio-
activity ofthe supernatant fluid was equal to
background. The washed pellets were dried
overnight in an oven at 70°C, and then
digested in 300 1Al of IM KOH for 1 h at 70°C.
After cooling to room temperature, 200 ,ul of
the digest was added to 18 ml of a methanol-
toluene scintillation fluid (700 ml of toluene,
300 ml ofmethanol, 3g ofPPO, and 100 mg of
POPOP) and the vials counted in a Beckman
LSC-230 liquid scintillation counter. The
3H-counting efficiency was 21%, and the
quench variation between samples was neg-
ligible. Results were expressed as the per-
centage of contol ofreplicate samples at each
MTX concentration. Control values were in
excess of 2000 ct/min and the variability
between replicates less than 5%.
The cellular uptake of MTX was deter-
mined over a 160-min interval, using identi-
cally prepared and incubated cell suspensions
in the presence of [3H]MTX (sp. act. 0 3
Ci/mmol) at concentrations of 1O-5M, 10-6M,
10-7M and 10-8M. Following 160-min incu-
bation, all suspensions were centrifuged at
700 gfor 5 min and the supernatant aspirated.
The cell pellets were washed twice by
resuspension in 4°C 0.85% NaCl solution and
recentrifugation. Membrane-bound drug is,
eliminated by this procedure, without loss of
intracellular MTX (Bender et al., 1975).
Further, cell attrition was less than 5% during
the wash procedure. The cell pellets were
dried overnight in an oven at 70°C and
prepared for scintillation counting as de-
scribed above. As pellets were too small to
weigh, uptakes were expressed as pmol/106
cells.
Treatment.-Patients were treated, on the
day following their baseline marrow studies,
with a 24-h infusion of MTX at a measured
plasma level of 0-3-10 x 10-6M, followed by
mg-equivalent leucovorin " rescue ", given
in divided doses at the termination of the
infusion and again 24 h later. Plasma MTX
concentrations were determined by the
method of Bertino (1964) on specimens
obtained twice during an infusion, excluding
the initial 6-h period during which the
peak level of the priming dose biased results
upward. In addition, 5 patients (K.R., J.F.,
P.M., C.F., and P.R.) also received a 12-h
infusion of cytosine arabinoside (Ara-C;
30 mg/M2) given daily for 3 days, commen-
cing 12 h after the cessation of the MTX
infusion. This was given to take advantage
ofthe potential " synchronizing effect " ofthe
MTX (Lampkin, McWilliams and Mauer,
1972). Chemotherapy cycles were ad-
ministered every 7-10 days, with dose
escalation as necessary to attain or exceed a
steady-state plasma concentration of 10-6M.
An evaluable treatment course consisted ofat
least 2 consecutive cycles of chemotherapy
(Table II). Response to therapy was evalu-
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TABLE II. Infusion Concentrations of MTX
Patient
K.R.
J.F.
P.M.
C.F.
D.B.
P.J.
K.T.
S.Ly
S.Li
P.R.
Treatment course
(no.)
1, 2
1, 2
1
2
3
1
2
3
1, 2
1, 2
1, 2
1, 2
1
2
1
2
ated by weekly bone marrow aspirates or
biopsies. Further, peripheral tumour masses
in Burkitt's lymphoma (BL) patients were
also followed. Progressive hypocellularity
withdiminution ofboth normal andmalignant
elements was not scored as a partial response,
unless the differential marrow blast cell count
dropped below 25%. Lowering of the peri-
pheral blast cell count was not scored as a
response, unless a marrow response occurred
concurrently. In the BL patients, extra-
medullary tumour was also evaluated for
response. A partial response was defined as
> 50%0 reduction in all evaluable peripheral
tumours in the presence of a partial marrow
response, as well. Complete responses were
defined as the return of an MI marrow with
normal peripheral blood counts.
Mean
steady-state MTX
level (lIM)
1-6
1-4
0-4
0- 75
1-6
0-3
0-9
2-15
6-8
3-0
7.9
10
0-7
4-0
1-2
3 -2
Ara-C
adminiistered
+
+
+
+v
RESULTS
Uptake of MTX by blast cells
The total intracellular MTX levels at
each of the respective experimental con-
centrations are illustrated in Fig. 1.
Mean increments ofintracellulardrug were
4*2, 4-4 and 3-6, with ten-fold changes of
extracellular drug concentration from
10-8 to 10-7, 10-7 to 10-6M and 10-6 to
10-5m respectively. A comparison of
mean intracellular drug levels between all
responsive and all unresponsive patients
at each MTX concentration fails to reveal
any significant differences. A similar
comparison in the sub-groups of acute
lymphocytic leukaemia (ALL) and BL
TABLE III. Total Intracellular MTX at Various Extrcacellular Concentrations
Clinical
Dx. response
AML
ALL
ALL
ALL
ALL
ALL
ALL
BL
BL
BL
N
C
N
N
N
N
N
p
p
N
10-5M 10-6M 10-7M 10 Som
1 -16
9-24
11 -30
13 -20
12-10
15-30
10-10
8-09
14-90
0-94
0-40
1 -20
4-25
4-20
4-19
3 -45
3-05
3 - 13
3 - 17
0-30
0-17
0-29
1 -60
2 - 10
1- 20
0 54
0-63
0-61
0-35
0-11
0-34
0-40
0-21
0-15
0-12
0-03
The data expressed represent the mean of duplicate determinations at 160 min of
uptake in each patient. The units are pmol/106 cells. The abbreviations used are N,
no response; C, complete response; and P, partial response.
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Patient
K.R.
J.F.
P.M.
C.F.
D.B.
P.J.
K.T.
S.Ly
S.Li
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FIG. 1. Total intracellular MTX in responding (Q) and non-responding (0) patients at various
extracellular MTX concentrations. Each point represents the mean4- s.e. of data contained
in Table III.
patients reveals a significant difference
only at a 10-6M extracellular concentra-
tion.
The exchangeable intracellular MTX
levels for each patient may be determined
by subtracting the mean non-exchangeable
drug levels for each cell type (Bender,
1975) from the total values in Table III.
The mean levels previously reported were
converted from MTX/mg dry cell weight
to MTX/106 cells by using the conversion
factor reported by Goldman et al. (1968)
for L1210 tumour cells. A human con-
version factor has not yet been deter-
mined. This conversion gives non-
exchangeable levels of 0.10, 0-17 and 0-15
pmol/106 cells for AML, ALL and BL
respectively. Appreciable levels of ex-
changeable intracellular MTX do not
accumulate at an extracellular concen-
tration of less than 10-7M. Above this
concentration, exchangeable intracellular
MTX increases rapidly. Mean exchange-
able levels are 0-08, 0-65, 2*58 and 9-45
pmol/106 cells at 10-8M, 1J0-7M, 10-6M
and 10-5M, respectively. Acomparison of
the mean exchangeable drug levels be-
tween all responsive and unresponsive
patients at each MTX concentration,
however, fails to reveal any significant
difference. Again, a similar comparison
of responders and non-responders in the
ALL and BL sub-groups reveals significant
differences at 10-6M.
Deoxyuridine incorporation studies
In vitro UdR incorporation studies
were performed on all patients on the day
prior to chemotherapy. These data are
illustrated in Fig. 2. A progressive de-
crease in UdR incorporation with increas-
ing MTX concentration is observed, with
an apparent "plateau " with further
increases from 10-6M to 10-5M. Only
PatientP.R. showedanysignificantchange
in UdR incorporation with this concen-
tration increment. A comparison of re-
sponders and non-responders reveals
significant differences at 10-6M and 10-5M.
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Fi;e. 2. UdR inicorporation at various extracellular MTX concentrations. Each point represents the meanAs.c. of UdR incorporation as determined1 in responders andl non-responders as listedl in Tablh III.
Further, a similar comparison between
responding and non-responding patients
in the ALL or BL subgroups reveals
significantdifferences inUdRincorporation
at 10-61m and 10-5M. All patients who
achieved either a complete or partial
response to therapy had UdR incorpora-
tion suppressed to less than 20%/ of con-
trol at 10-6M MTX, a level commensurate
with their actual plasma concentration
during treatment. Further, a ten-fold
increase in extracellular MTX from 1 -6M
to 10-5M produced no further suppression
of UdR incorporation. This " plateau "
effect is illustrated in Fig. 2 (responder
curve). A similar relationship appears to
exist for non-responders, as the UdR
incorporation values at 10-6M and 10-5M
do not significantly differ, although in-
spection of the curve reveals a small
changeoverthisinterval. The " plateau "
effect observed in Fig. 2 is also apparent
when the UdR incorporation is plotted
against total intracellular MTX (Fig. 3).
Although a linear relationship appears to
exist on the non-responder curve, UdR
incorporation values at total intracellular
MTX levels in excess of 1.0 pmol/106 cells
do not significantly differ.
Re8ponse to therapy
Three of the 10 patients treated
achieved a clinical response. Patient J. F.
achieved a complete bone-marrow remis-
sion with two cvcles of the MTX/Ara-C'
combination. The duration of remission
was 6 weeks before the marrow repopu-
lated with tuimour. Patient S.Ly
achieved a partial marrow and extra-
medullary response lasting 27 days with
3 cycles of MTX alone, before succumbing
to unresponsive progressive disease.
Patient S.Li received MTX alone, and
achieved a partial marrow response lasting
30 days with 2 cycles of chemotherapy,
before succumbing to progressive un-
responsive disease. The mean survival
of responders was 81 days (range 35-156
days). The remaining 7 patients did not
fulfill the minimum requirements for a
partial response as defined earlier. Their
mean survival was 203 days (range 14-
530 days). The shorter survival of re-
sponders results from the fact that 2 ofthe
3 had BL which initially responded to
therapy and then rapidly recurred leading
to death, and the fact that 2 of the non-
responders with ALL lived in excess of I
year after failing MTX.
48(9
10_R. A. BENDER, W. A. BLEYER, J. C. DRAKE AND J. L. ZIEGLER
100
0
c 90
0
NO 80
Z 70
0
< 60
0
C: 50
0
Z 40
z
D 30
a:
>. 20
x
0
a 10
0
0.10 1.0 10.0 100.0
TOTAL INTRACELLULAR MTX (pmol /106 cells)
FIG. 3. Deoxyuridine incorporation at various intracellular MTX levels. Each poiit represeints
the meant s.e. of UdR incorporation as a function of mean total intracellular MTX in responders
and non-responders as listed in Table III.
DISCUSSION
The transmembrane movement of
MTX in human leukaemic blasts is com-
patible with a carrier-mediated process
(Bender, 1975; Kessel, Hall and Roberts,
1968). The drug must enter the cell, bind
to DHFR, and perhaps accumulate in
excess of these high-affinity sites (Gold-
man, 1974) to exert a maximum cytocidal
effect. Cellular resistance to MTX is
likely related to any and all factors which
may influence these parameters (Bender,
1975). It is of value, then, to prospec-
tively assess patient response to drug
therapy, based on pre-treatment evalu-
ation. Such prospective assessments take
on special relevance in the treatment of
" drug-resistant " patients, when the
chances of a clinical response to arandomly
selected agent may be minimal. Further,
the ability to study the dominant site of
tumour involvement is important, in the
light of recent data suggesting that peri-
pheral blasts are more sensitive to MTX
suppression of DNA synthesis than are
marrow blasts in vitro (Hryniuk et al.,
1974).
The patients examined were all " drug-
resistant" by virtue of failing treatment
with multiple agents, alone and in com-
bination, prior to being acceptable for this
study. Of the three responders (1 com-
plete and 2 partial), one received the
MTX-Ara-C combination. Although it is
difficult to determine which of the two
agents was instrumental in his response,
the very low response rate of ALL to
Ara-C (Livingston and Carter, 1970)
makes it more likely that the observed
response was to the MTX infusion. As
such, the potential predictive value of the
total intracellular MTX, the exchangeable
intracellular MTX, or the suppressibility
of UdR incorporation by MTX has special
significance.
The total intracellular MTX increases
four-fold for each ten-fold increase in the
extracellular MTX concentration up to
10-5M, the limits of this study. Uptake
values at 10-6M, the plasma concentration
maintained during actual treatment, do
not correlate with response in an overall
analysis. However, the responding ALL
patient had significantly less intracellular
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drug, and the responding BL patient had
significantly morethanthenon-responders,
in each respective group. Such diversity
suggests little value for total uptake as a
predictive test. Similarly, exchangeable
intracellular drug was not of predictive
value. Other investigators (Hall et al.,
1966; Kessel et al., 1968) have suggested
that drug uptake over a short interval
(i.e. 15 min) was greater in ALL and AML
patients subsequently responding to MTX
therapy. However, such short incubation
times at low MTX concentrations (i.e.
2 x 10-7M) reflect only unidirectional
influx and hence membrane permeability.
The other factors affecting total intra-
cellular drug are not examined by such
studies; longer incubation times are neces-
sary to evaluate them. The relationship
between exchangeable intracellular MTX
and UdR incorporation is similar to that
seen for total and exchangeable intra-
cellular drug. However, a cytocidal role
of exchangeable intracellular drug may be
suggested by the necessity to achieve
extracellular MTX concentrations of at
least 10-6M, to inhibit DNA synthesis
maximally when high-affinity sites are
saturated at concentrations of 10-7M.
The dichotomy between responders
and non-responders is best illustrated by
the relationship between the UdR incor-
poration and the extracellular MTX con-
centration (Fig. 2). UdR incorporation
rapidly declines from 10-8M to 10-6M,
where an apparent " plateau " is reached.
Further increases in extracellular MTX
produce no further inhibition of DNA
synthesis. All those patients whose UdR
incorporation was < 20% of control at
] 0-6m responded to treatment; conversely,
all patients with UdR incorporation
> 4000 of control did not. No patient
had values in the 20% to 40% range,
although the study by Necheles et al.
(1968) suggests that suppression to 35%
of control or less is associated with a
response to therapy. A concentration
threshold for suppression of DNA syn-
thesis in a responding patient population
is again suggested. Non-responding
patients had a progressive decline of UdR
incorporation with increasing MTX con-
centration, with an insignificant change
in the 1O-6M-1O-5m range. While the
extracellular MTX concentrations required
to suppress DNA synthesis to < 200% of
control are identical to those described by
Hryniuk and Bertino (1969), they found
no correlation between in vitro suppression
and clinical response. However, when
they carried out the identical study on
blast cells obtained during the first MTX
infusion, responding patients had signifi-
cantly more inhibition of UdR incorpora-
tion than non-responders. The reasons
for this disparity of results is unclear.
Recent studies by Hryniuk et al. (1974)
further support the utility of such in vitro
studies as predictors of clinical response.
It is likely that all responsive tumours
have different concentration thresholds
and that further application of in vitro
tests may allow identification of these
values, so that appropriate drug concen-
trations can be achieved during treatment,
and undue toxicity from excessive concen-
trations avoided.
The authors would like to acknowledge
the assistance of Dr Brigid G. Leventhal
in acquiring patient material.
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